Becton, Dickinson and Company (BDX) is showing signs of growth recovery as the company delivered a clean fiscal Q2 beat and raised its fiscal 2026 EPS outlook, RBC Capital Markets said in a note emailed Friday.

The firm said the Q2 beat is a positive indicator of improving business performance, with growth across multiple platforms. Meanwhile, the company's growth recovery back into mid-single-digit profile is yet to be proven out, it added.

RBC said known headwinds such as Alaris, China and vaccines are playing out as anticipated and should ease over time.

The company remains focused on share repurchases, returning about $2.3 billion to shareholders during the quarter, analysts noted.

The firm also highlighted momentum in biologic, GLP-1 delivery systems and Pyxis Pro, which it said is generating strong early competitive traction.

RBC maintained its sector perform rating on Becton, Dickinson and a $175 price target.

Price: 148.13, Change: -5.13, Percent Change: -3.35